Sagent Pharmaceuticals (SGNT) To Benefit From Obama's Executive Order - Jefferies

President Obama executive order to help ease the nation's current drug shortage will benefit Sagent Pharmaceuticals (NASDAQ: SGNT), according to analysts at Jefferies.

"With several shortage products already pending FDA approval, and a new manufacturing facility awaiting FDA inspection, Sagent should benefit from any FDA efforts to accelerate shortage approvals," analyst Corey Davis said in a research report today.

The firm reiterated their Buy rating and $28 price target.

For more ratings news on Sagent Pharmaceuticals click here and for the rating history of Sagent Pharmaceuticals click here.

Shares of Sagent Pharmaceuticals closed at $25.55 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
• Kepler Cheuvreux Downgrades Avantium N.V (AVTX:NA) to Reduce
• Jefferies Upgrades Fortescue Metals Group Ltd. (FMG:AU) (FSUGY) to Hold